Lu Yang

Dr. Lu Yang

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2026 in Translational Oncology
Verified
Journal Article
Open access
FWFang Wei
Fang Wei
LYLu Yang
Lu Yang
XZXianghai Zeng
Xianghai Zeng
QWQian Wang
Qian Wang
ZWZiqi Wang
Ziqi Wang
XYXianglin Yuan
Xianglin Yuan
Pancreatic ductal adenocarcinoma is a malignancy characterized by profound immunosuppression and universal resistance to immunotherapy. The complex tumor microenvironment is a critical determinant of therapeutic failure. The chemokine C-X-C motif chemokine ligand 11 (CXCL11) exerts dual immunomodulatory roles in various tumors; however, its expression pattern, clinical significance, and molecular mechanisms in pancreatic cancer remain unclear. This study integrated clinical cohort analysis, tissue microarray, transcriptomic sequencing, and in vitro functional experiments. Immunohistochemistry and multiplex immunofluorescence were used to analyze CXCL11 expression and its spatial relationship with immune cell infiltration. Transcriptomic sequencing was performed to identify differentially expressed genes after CXCL11 knockdown, followed by pathway enrichment analysis. CXCL11 knockdown and overexpression models were established in Panc02 and SW1990 cell lines, and western blotting was used to verify the regulatory effects on the nuclear factor kappa-B (NF-κB) signaling pathway and downstream CC motif chemokine ligand 2 (CCL2) expression. CXCL11 expression was higher in paratumor tissues than in tumor tissues of pancreatic cancer, and its high expression was significantly associated with shortened overall survival and more aggressive pathological features. Co-enrichement of CXCL11 with immunosuppressive markers such as CD163, CD11b, and programmed death-ligand 1 in paratumoral regions suggests its involvement in forming a spatially heterogeneous immunosuppressive barrier. Tissue-level analysis revealed a significant positive correlation between CXCL11 expression and the M2 macrophage marker CD163, as well as the myeloid-derived suppressor cell marker CD11b. Transcriptomic and functional experiments confirmed that CXCL11 activates the NF-κB signaling pathway and upregulates CCL2 expression. Tissue microarray further validated their positive correlations at the protein level. CXCL11 plays a pro-tumorigenic role in pancreatic cancer, with high expression levels predicting poor prognosis. By activating the NF-κB signaling pathway to upregulate CCL2, CXCL11 drives the "CXCL11-NF-κB-CCL2″ signaling axis, which, together with its enrichment in paratumoral regions, promotes the recruitment and activation of immunosuppressive cells and forms a functional immunosuppressive barrier at the invasive front. This provides a mechanistic explanation for immunotherapeutic resistance in pancreatic cancer and suggests CXCL11 and its related pathways as potential therapeutic targets.

7 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LYLu Yang
Lu Yang
YHYuting Huang
Yuting Huang
ALAndong Liu
Andong Liu
YYYuanmei Yan
Yuanmei Yan
BLBo Liu
Bo Liu
XYXianglin Yuan
Xianglin Yuan
Pulmonary fibrosis is a frequent complication of abnormal tissue repair following lung injury by many causes. It can be found in various diseases and clinical conditions, such as idiopathic pulmonary fibrosis, cancer-treatment-induced lung injury, and other occupational, environmental, and autoimmune lung diseases. Though the initiating factors of these conditions are different, they have several biological mechanisms in common during disease progression, such as injury to and abnormal repair of alveolar epithelial and vascular endothelial cells, immune microenvironment remodeling, macrophage reprogramming, persistent activation of fibroblasts, excessive extracellular matrix deposition, and mechanically driven positive feedback loops. Recent single-cell and spatial multi-omics developments have changed the direction of pulmonary fibrosis research to concentrate on individual signaling pathways to obtain a wider perspective of interactions between cell types. These investigations have discovered significant cell populations, such as abnormal basal-like epithelial cells, SPP1+/TREM2+ profibrotic macrophages, and CTHRC1+ pathological fibroblasts. They have also uncovered new processes, including metabolic–epigenetic interactions, endothelial-to-mesenchymal transition, and macrophage-to-myofibroblast transition that give a new understanding to the pathogenesis of diseases. Pirfenidone and nintedanib may slow the progression of lung dysfunction but do not reverse already existing fibrosis. Thus, knowledge of the complicated cellular and molecular processes of pulmonary fibrosis is critical in determining new therapeutic targets and enhancing existing therapies. This review summarizes pathological characteristics, mechanisms and therapeutic breakthroughs with special emphasis on idiopathic pulmonary fibrosis and cancer-therapy-related lung damage and discusses emerging strategies targeting epithelial repair, endothelial barrier activity, macrophage activity, fibroblast activation, and extracellular matrix remodeling.